Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Barry Quart Sells 6,901 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 6,901 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $50.00, for a total transaction of $345,050.00. Following the transaction, the director owned 12,546 shares of the company’s stock, valued at approximately $627,300. This represents a 35.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Trading Down 3.9%

KNSA traded down $1.91 during trading on Wednesday, reaching $47.03. 600,454 shares of the company’s stock were exchanged, compared to its average volume of 647,366. Kiniksa Pharmaceuticals International, plc has a one year low of $18.25 and a one year high of $50.03. The stock has a market capitalization of $3.60 billion, a PE ratio of 63.55 and a beta of 0.06. The firm has a fifty day moving average price of $45.75 and a two-hundred day moving average price of $42.13.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The business had revenue of $202.13 million for the quarter, compared to the consensus estimate of $200.86 million. During the same period in the previous year, the firm earned ($0.12) earnings per share. The company’s revenue was up 65.0% compared to the same quarter last year. Sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Institutional investors have recently modified their holdings of the company. USA Financial Formulas bought a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at $32,000. Smartleaf Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at $36,000. EverSource Wealth Advisors LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the last quarter. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at $41,000. Finally, CIBC Private Wealth Group LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at $41,000. 53.95% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Finally, Wells Fargo & Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $55.29.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.